DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Lakshman, A. [1 ]
Abeykoon, J. [2 ]
Kumar, S. [1 ]
Rajkumar, V. [1 ]
Kourelis, T. [1 ]
Buadi, F. [1 ]
Dingli, D. [1 ]
Martha, L. [1 ]
Gonsalves, W. [1 ]
Dispenzieri, A. [1 ]
Kyle, R. [1 ]
Lin, Y. [1 ]
Go, R. [1 ]
Warsame, R. [1 ]
Hobbs, M. [1 ]
Fonder, A. [1 ]
Hwa, Y. [1 ]
Hayman, S. [1 ]
Russell, S. [1 ]
Leung, N. [1 ]
Gertz, M. [1 ]
Kapoor, P. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Internal Med, Rochester, MN USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1240
引用
收藏
页码：508 / 508
页数：1
相关论文
共 50 条
  • [31] Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study
    Han, Xiaoyan
    Jiang, Xincheng
    He, Jingsong
    Zheng, Gaofeng
    Xiong, Yaqin
    Wen, Yanling
    Yang, Yang
    He, Donghua
    Chen, Qingxiao
    Wu, Wenjun
    Zhao, Yi
    Li, Yi
    Cai, Zhen
    BLOOD, 2023, 142
  • [32] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Blair, Hannah A.
    DRUGS, 2017, 77 (18) : 2013 - 2024
  • [33] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2017, 77 : 2013 - 2024
  • [34] Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma
    Kumar, Shaji K.
    Durie, Brian G. M.
    Su, Zhuo
    Diels, Joris
    Hutton, Brian
    Lam, Annette
    Tetsuro, Ito
    BLOOD, 2016, 128 (22)
  • [35] Efficacy and Safety of Daratumumab-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma - A Systematic Literature Review and Network Meta-analysis
    Dimopoulos, Meletios
    Weisel, Katja
    Kaufman, Jonathan L.
    Sonneveld, Pieter
    Rizzo, Maria
    Xu, Yingxin
    Fahrbach, Kyle
    Gaudig, Maren
    Slavcev, Mary
    Lam, Annette
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E63 - E63
  • [36] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [37] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    International Journal of Hematology, 2018, 107 : 460 - 467
  • [38] NURSING IMPLICATIONS FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA RECEIVING COMBINATION THERAPY WITH DARATUMUMAB (DARZALEX®).
    Catamero, Donna
    Morgan, Gillian
    Florendo, Erika
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [39] Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany
    Steinmetz, H. Tilman
    Singh, Moushmi
    Milce, Joseph
    Haidar, Mohamad
    Rieth, Achim
    Lebioda, Andrea
    Kohnke, Jorn
    ADVANCES IN THERAPY, 2022, 39 (03) : 1247 - 1266
  • [40] Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    Kim, Inho
    Jo, Jaemin
    Park, Hyunkyung
    Lee, Jeong-Ok
    Lee, Jiyun
    ANTICANCER RESEARCH, 2019, 39 (09) : 5165 - 5170
12345